{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:53:58Z","timestamp":1790985238303,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T00:00:00Z","timestamp":1403740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s12032-014-0076-7","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T10:56:58Z","timestamp":1403693818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study"],"prefix":"10.1007","volume":"31","author":[{"given":"Jalid","family":"Sehouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pietzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Salat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Berton-Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tr\u00e9dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Tournigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Dudnichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilke","family":"Friccius-Quecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,26]]},"reference":[{"key":"76_CR1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","volume":"198","author":"RA Adam","year":"2004","unstructured":"Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198:999\u20131011.","journal-title":"J Am Coll Surg"},{"key":"76_CR2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl499","volume":"18","author":"AA Ayantunde","year":"2007","unstructured":"Ayantunde AA, Parsons S. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18:945\u20139.","journal-title":"Ann Oncol"},{"key":"76_CR3","first-page":"109","volume":"134","author":"J Tamsma","year":"2007","unstructured":"Tamsma J. The pathogenesis of malignant ascites. Cancer Treat Res. 2007;134:109\u201318.","journal-title":"Cancer Treat Res"},{"key":"76_CR4","first-page":"474","volume":"6","author":"JR Mackey","year":"1996","unstructured":"Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol. 1996;6:474\u201380.","journal-title":"Can J Oncol"},{"key":"76_CR5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","volume":"100","author":"M Valle","year":"2009","unstructured":"Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. Surg Oncol. 2009;100:331\u20134.","journal-title":"Surg Oncol"},{"key":"76_CR6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/bjs.1800830104","volume":"83","author":"SL Parsons","year":"1996","unstructured":"Parsons SL, Watson SA, Steele RJC. Malignant ascites. Br J Surg. 1996;83:6\u201314.","journal-title":"Br J Surg"},{"key":"76_CR7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","volume":"42","author":"G Becker","year":"2006","unstructured":"Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42:589\u201397.","journal-title":"Eur J Cancer"},{"key":"76_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18:1\u20139.","journal-title":"Int J Clin Oncol"},{"key":"76_CR9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2010.07.016","volume":"79","author":"S Barni","year":"2011","unstructured":"Barni S, Cabiddu M, Ghilardi M, Petrelli F. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol. 2011;79:144\u201353.","journal-title":"Crit Rev Oncol Hematol"},{"key":"76_CR10","first-page":"3353","volume":"29","author":"H Woopen","year":"2009","unstructured":"Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res. 2009;29:3353\u20139.","journal-title":"Anticancer Res"},{"key":"76_CR11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","volume":"36","author":"D Seimetz","year":"2010","unstructured":"Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM \u00d7 anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010;36:458\u201367.","journal-title":"Cancer Treat Rev"},{"key":"76_CR12","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1182\/blood.V98.8.2526","volume":"98","author":"P Ruf","year":"2001","unstructured":"Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001;98:2526\u201334.","journal-title":"Blood"},{"key":"76_CR13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjc.6603881","volume":"97","author":"P Ruf","year":"2007","unstructured":"Ruf P, Gires O, J\u00e4ger M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007;97:315\u201321.","journal-title":"Br J Cancer"},{"key":"76_CR14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1054\/bjoc.2000.1237","volume":"83","author":"R Zeidler","year":"2000","unstructured":"Zeidler R, Mysliwietz J, Cs\u00e1nady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83:261\u20136.","journal-title":"Br J Cancer"},{"key":"76_CR15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/0008-5472.CAN-11-2235","volume":"72","author":"M J\u00e4ger","year":"2012","unstructured":"J\u00e4ger M, Schobert A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Str\u00f6hlein M, Theissen B, Heiss MM, Lindhofer H. Immunomonitoring results of a phase II\/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM \u00d7 anti-CD3). Cancer Res. 2012;72:24\u201332.","journal-title":"Cancer Res"},{"key":"76_CR16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/002215540104900711","volume":"49","author":"R Riesenberg","year":"2001","unstructured":"Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (\u03b1Ep-CAM\u00a0\u00d7\u00a0\u03b1CD3). J Histochem Cytochem. 2001;49:911\u20137.","journal-title":"J Histochem Cytochem"},{"key":"76_CR17","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.163.3.1246","volume":"163","author":"R Zeidler","year":"1999","unstructured":"Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumour cell killing. J Immunol. 1999;163:1246\u201352.","journal-title":"J Immunol"},{"key":"76_CR18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","volume":"35","author":"P Went","year":"2004","unstructured":"Went P, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCAM protein expression in human carcinomas. Hum Pathol. 2004;35:122\u20138.","journal-title":"Hum Pathol"},{"key":"76_CR19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.bjc.6602924","volume":"94","author":"P Went","year":"2006","unstructured":"Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94:128\u201335.","journal-title":"Br J Cancer"},{"key":"76_CR20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/jcp.2011.090274","volume":"64","author":"G Spizzo","year":"2011","unstructured":"Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, Mazzoleni G, Gastl G, Went P. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. Clin Pathol. 2011;64:415\u201320.","journal-title":"Clin Pathol"},{"key":"76_CR21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2011.04.002","volume":"38","author":"C Patriarca","year":"2012","unstructured":"Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012;38:68\u201375.","journal-title":"Cancer Treat Rev"},{"key":"76_CR22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ncb1824","volume":"11","author":"D Maetzel","year":"2009","unstructured":"Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11:162\u201371.","journal-title":"Nat Cell Biol"},{"key":"76_CR23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.cdd.4402283","volume":"15","author":"A Eramo","year":"2008","unstructured":"Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504\u201314.","journal-title":"Cell Death Differ"},{"key":"76_CR24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature05384","volume":"445","author":"L Ricci-Vitiani","year":"2007","unstructured":"Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111\u20135.","journal-title":"Nature"},{"key":"76_CR25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/B:BREA.0000036787.59816.01","volume":"86","author":"G Spizzo","year":"2004","unstructured":"Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, K\u00f6chli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004;86:207\u201313.","journal-title":"Breast Cancer Res Treat"},{"key":"76_CR26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s004280050393","volume":"435","author":"B Davidson","year":"1999","unstructured":"Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bj\u00e5mer A, Berner A. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies: evaluation of five epithelial markers. Virchows Arch. 1999;435:43\u20139.","journal-title":"Virchows Arch"},{"key":"76_CR27","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1158\/1078-0432.CCR-05-0043","volume":"11","author":"K Passebosc-Faure","year":"2005","unstructured":"Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, P\u00e9rol M, Genin C. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res. 2005;11:6862\u20137.","journal-title":"Clin Cancer Res"},{"key":"76_CR28","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","volume":"13","author":"A Burges","year":"2007","unstructured":"Burges A, Wimberger P, K\u00fcmper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, J\u00e4ger M, Str\u00f6hlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I\/II study. Clin Cancer Res. 2007;13:3899\u2013905.","journal-title":"Clin Cancer Res"},{"key":"76_CR29","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127:2209\u201321.","journal-title":"Int J Cancer"},{"key":"76_CR30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mds178","volume":"23","author":"P Wimberger","year":"2012","unstructured":"Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran SE, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23:1979\u201385.","journal-title":"Ann Oncol"},{"key":"76_CR31","first-page":"4239","volume":"25","author":"A Walz","year":"2005","unstructured":"Walz A, Andratschke M, Wollenberg B, Lindhofer H, Zeidler R. Prednisolone reduces TNF-alpha release by PBMCs activated with a trifunctional bispecific antibody but not their anti-tumor activity. Anticancer Res. 2005;25:4239\u201343.","journal-title":"Anticancer Res"},{"key":"76_CR32","doi-asserted-by":"crossref","unstructured":"Berek JS, Edwards RP, Parker L, DeMars LR, Herzog TJ, Lentz SS, Morris R, Akerley WL, Holloway RW, Method M, Plaxe SC, Walker JL, Schindler T, Schulze E, Krasner CN. Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. J Clin Oncol. 2011;29(Suppl.) (abstract 5048).","DOI":"10.1200\/jco.2011.29.15_suppl.5048"},{"key":"76_CR33","doi-asserted-by":"crossref","unstructured":"Sehouli J, Reinthaller A, Marth C, Reimer D, Reimer T, Stummvoll W, Angleitner-Boubenizek L, Lehnert B, Marquardt M, Essing MM, Chekerov R. Intra- and post-operative catumaxomab in patients with epithelial ovarian cancer: two-year efficacy results from a multicenter, single-arm, phase II study. J Clin Oncol. 2011;29(Suppl.) (Abstract 5082).","DOI":"10.1200\/jco.2011.29.15_suppl.5082"},{"key":"76_CR34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2011.06.004","volume":"123","author":"K Baumann","year":"2011","unstructured":"Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, L\u00fcck HJ, Wagner U. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol. 2011;123:27\u201332.","journal-title":"Gynecol Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0076-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-014-0076-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0076-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T15:23:20Z","timestamp":1689348200000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-014-0076-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,26]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1007\/s12032-014-0076-7","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,26]]},"article-number":"76"}}